PDL Settles Novartis IP Row With Lucentis Payments
PDL BioPharma Inc. on Monday said it had resolved a wide-ranging patent battle with Novartis AG by agreeing to pay the Swiss drug giant an unspecified amount based on its sales...To view the full article, register now.
Already a subscriber? Click here to view full article